EA201590613A1 - Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения - Google Patents

Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения

Info

Publication number
EA201590613A1
EA201590613A1 EA201590613A EA201590613A EA201590613A1 EA 201590613 A1 EA201590613 A1 EA 201590613A1 EA 201590613 A EA201590613 A EA 201590613A EA 201590613 A EA201590613 A EA 201590613A EA 201590613 A1 EA201590613 A1 EA 201590613A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
bind
antigen binding
binding molecules
bispecific antigen
Prior art date
Application number
EA201590613A
Other languages
English (en)
Other versions
EA033400B1 (ru
Inventor
Эрик Смит
Николас Дж. Пападопулос
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201590613(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201590613A1 publication Critical patent/EA201590613A1/ru
Publication of EA033400B1 publication Critical patent/EA033400B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Secondary Cells (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Prostheses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение относится к антителам, которые связываются с CD3, и к способам их использования. Согласно определенным вариантам осуществления антитела по изобретению связываются с CD3 человека с высокой аффинностью и индуцируют пролиферацию Т-клеток человека. Изобретение относится к антителам, которые связываются с CD3 и индуцируют опосредованный Т-клетками цитолиз опухолевых клеток. Согласно определенным вариантам осуществления настоящее изобретение относится к биспецифическим антигенсвязывающим молекулам, содержащим первый антигенсвязывающий домен, который специфически связывается с CD3 человека, и вторую антигенсвязывающую молекулу, которая специфически связывается с CD20 человека. В определенных вариантах осуществления биспецифические антигенсвязывающие молекулы по настоящему изобретению способны ингибировать рост В-клеточных опухолей, экспрессирующих CD20. Антитела и биспецифические антигенсвязывающие молекулы по изобретению подходят для лечения заболеваний и нарушений, при которых желательным и/или терапевтически эффективным является активированный или индуцированный целевой иммунный ответ. Например, антитела по изобретению подходят для лечения различных злокачественных опухолей, а также других связанных с CD20 заболеваний и нарушений.
EA201590613A 2012-09-21 2013-09-19 Антитело против cd3 и его применение EA033400B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261704029P 2012-09-21 2012-09-21
US201361753461P 2013-01-17 2013-01-17
US201361763110P 2013-02-11 2013-02-11
US201361827098P 2013-05-24 2013-05-24
PCT/US2013/060511 WO2014047231A1 (en) 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

Publications (2)

Publication Number Publication Date
EA201590613A1 true EA201590613A1 (ru) 2015-08-31
EA033400B1 EA033400B1 (ru) 2019-10-31

Family

ID=49304338

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590613A EA033400B1 (ru) 2012-09-21 2013-09-19 Антитело против cd3 и его применение

Country Status (33)

Country Link
US (4) US9657102B2 (ru)
EP (3) EP2897981B1 (ru)
JP (5) JP6923292B2 (ru)
KR (2) KR102470709B1 (ru)
CN (3) CN113980132A (ru)
AR (1) AR092612A1 (ru)
AU (3) AU2013318059C1 (ru)
BR (1) BR112015005380B1 (ru)
CA (2) CA2885156C (ru)
CL (3) CL2015000713A1 (ru)
CO (1) CO7400860A2 (ru)
DK (2) DK2897981T3 (ru)
EA (1) EA033400B1 (ru)
ES (2) ES2948807T3 (ru)
FI (2) FI3778641T3 (ru)
HK (1) HK1212996A1 (ru)
HR (2) HRP20240149T1 (ru)
HU (2) HUE065481T2 (ru)
IL (2) IL237301B (ru)
JO (3) JOP20200236A1 (ru)
LT (2) LT2897981T (ru)
MX (2) MX2015003206A (ru)
MY (1) MY179577A (ru)
NZ (2) NZ742078A (ru)
PH (2) PH12015500328B1 (ru)
PL (2) PL2897981T3 (ru)
PT (2) PT2897981T (ru)
RS (2) RS64378B1 (ru)
SG (3) SG10202111095XA (ru)
SI (2) SI2897981T1 (ru)
TW (4) TW202039579A (ru)
UY (1) UY35042A (ru)
WO (1) WO2014047231A1 (ru)

Families Citing this family (268)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2647707T (pt) 2010-11-30 2018-11-15 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de toxicidade
MX356947B (es) 2011-08-23 2018-06-20 Roche Glycart Ag Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014056783A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
EP2943511B1 (en) 2013-01-14 2019-08-07 Xencor, Inc. Novel heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
DK2961771T3 (da) 2013-02-26 2020-03-02 Roche Glycart Ag Bispecifikke, T-celle-aktiverende, antigenbindende molekyler, der er specifikke for CD3 og CEA
EP2961773B1 (en) 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2014145907A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
ES2683268T3 (es) 2013-07-25 2018-09-25 Cytomx Therapeutics, Inc. Anticuerpos multiespecíficos, anticuerpos activables multiespecíficos y métodos para usar los mismos
PE20210107A1 (es) 2013-12-17 2021-01-19 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
US10106623B2 (en) 2014-02-12 2018-10-23 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
EP3130606B1 (en) 2014-04-07 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Immunoactivating bispecific antibodies
CA2947157A1 (en) * 2014-05-13 2015-11-19 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
EP3172235A2 (en) 2014-07-25 2017-05-31 Cytomx Therapeutics Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MA50584A (fr) 2014-08-04 2020-09-16 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène activant des lymphocytes t
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
CA2958479A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
EP3201227A4 (en) 2014-09-29 2018-04-18 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
WO2016077720A1 (en) * 2014-11-14 2016-05-19 Protein One, Llc Binding agents and uses thereof
KR102614189B1 (ko) 2014-11-17 2023-12-18 리제너론 파아마슈티컬스, 인크. Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
CA2966566C (en) 2014-11-20 2024-03-19 F. Hoffmann-La Roche Ag Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists
CN113016720B (zh) 2014-11-24 2023-02-21 瑞泽恩制药公司 表达人源化cd3复合物的非人类动物
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
MA41019A (fr) 2014-11-26 2021-05-05 Xencor Inc Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
EP3223845B1 (en) 2014-11-26 2021-05-19 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
HUE045216T2 (hu) 2014-12-05 2019-12-30 Hoffmann La Roche Anti-CD79B antitestek és alkalmazási eljárások
WO2016089610A1 (en) 2014-12-06 2016-06-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
ES2717308T3 (es) 2014-12-06 2019-06-20 Gemoab Monoclonals Gmbh Células madre pluri- o multi-potentes genéticamente modificadas y sus usos
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
EP3242682A1 (en) * 2015-01-08 2017-11-15 Genmab A/S Bispecific antibodies against cd3 and cd20
WO2016141303A2 (en) * 2015-03-04 2016-09-09 Igm Biosciences, Inc. Cd20 binding molecules and uses thereof
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
EP3271022A4 (en) 2015-03-19 2018-10-31 Duke University Hiv-1 neutralizing antibodies and uses thereof
WO2016149695A1 (en) 2015-03-19 2016-09-22 Duke University HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (CD4bs ANTIBODIES)
WO2016149698A2 (en) 2015-03-19 2016-09-22 Duke University Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies)
WO2016149710A2 (en) 2015-03-19 2016-09-22 Duke University Hiv-1 neutralizing antibodies and uses thereof
EP3277725B1 (en) 2015-03-30 2020-11-25 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
EP4059514A1 (en) * 2015-05-08 2022-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
EA039429B1 (ru) * 2015-05-13 2022-01-26 Ридженерон Фармасьютикалз, Инк. Способы лечения опухолей с применением биспецифического антитела cd3xcd20
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3303400B1 (en) * 2015-05-28 2020-09-09 Genentech, Inc. Cell-based assay for detecting anti-cd3 homodimers
CN104931699A (zh) * 2015-05-29 2015-09-23 北京海思特临床检验所有限公司 骨髓涂片异常淋巴细胞染色试剂盒及其使用方法
SG10202110887PA (en) * 2015-06-09 2021-11-29 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
IL256079B2 (en) 2015-06-16 2024-01-01 Genentech Inc Human antibodies with improved affinity to FCRH5 - and methods of use
RU2020124105A (ru) 2015-06-24 2020-09-18 Ф. Хоффманн-Ля Рош Аг Антитела против трансферринового рецептора, обладающие индивидуализированной аффинностью
WO2017005649A1 (en) * 2015-07-09 2017-01-12 Genmab A/S Bispecific and multispecific antibodies and method for isolation of such
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
LT3353212T (lt) * 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
DK3356401T3 (da) 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CR20180149A (es) 2015-10-02 2018-04-05 Hoffmann La Roche Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP7044700B2 (ja) 2015-10-02 2022-03-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
PL3365366T3 (pl) 2015-10-25 2022-01-31 Sanofi Trójspecyficzne i/lub trójwalentne białka wiążące do zapobiegania lub leczenia zakażenia HIV
EP3378488A4 (en) * 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
WO2017086367A1 (ja) * 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
CN106810611A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
CN106810610A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
CN115920030A (zh) 2015-12-09 2023-04-07 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于降低抗药物抗体形成
HUE063377T2 (hu) 2015-12-22 2024-01-28 Regeneron Pharma Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
CN108368179B (zh) 2016-01-08 2022-08-23 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
US11513127B2 (en) 2016-01-25 2022-11-29 Genentech, Inc. Methods for assaying T-cell dependent bispecific antibodies
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
SG11201807936VA (en) * 2016-03-14 2018-10-30 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
LT3433280T (lt) 2016-03-22 2023-07-10 F. Hoffmann-La Roche Ag Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
RS64771B1 (sr) 2016-04-13 2023-11-30 Sanofi Sa Trispecifični i/ili trovalentni vezujući proteini
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
JP7134868B2 (ja) 2016-04-20 2022-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 発現強化座位の使用に基づく抗体を作製するための組成物および方法
TWI827531B (zh) 2016-04-20 2024-01-01 美商再生元醫藥公司 基於使用增強表現基因座之製備抗體的組成物及方法
TW202408578A (zh) 2016-05-13 2024-03-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
AU2017267793B2 (en) * 2016-05-20 2024-01-25 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
US10865230B2 (en) * 2016-05-27 2020-12-15 Altor Bioscience, Llc Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
RU2022104399A (ru) 2016-06-14 2022-05-05 Ксенкор, Инк. Биспецифические антитела-ингибиторы контрольных точек
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
EP3471773A4 (en) 2016-06-21 2020-07-08 Teneobio, Inc. ANTIBODIES BINDING CD3
EP3502142B1 (en) 2016-06-22 2021-10-27 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Bispecific antibody and antibody conjugate for tumour therapy and use thereof
CN116063545A (zh) 2016-06-28 2023-05-05 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
CN107573416A (zh) * 2016-06-30 2018-01-12 中国科学院深圳先进技术研究院 抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
WO2018013797A1 (en) 2016-07-13 2018-01-18 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CN106317226B (zh) * 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP7030109B2 (ja) 2016-09-14 2022-03-04 テネオバイオ， インコーポレイテッド Ｃｄ３結合抗体
US10941208B2 (en) 2016-09-23 2021-03-09 Regeneron Pharmaceuticals, Inc. Anti-MUC16 antibodies
EA201990781A9 (ru) 2016-09-23 2019-11-27 Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
PL3519437T3 (pl) 2016-09-30 2022-01-17 F. Hoffmann-La Roche Ag Przeciwciała dwuswoiste przeciwko p95HER2
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression
KR102649972B1 (ko) 2016-10-14 2024-03-22 젠코어 인코포레이티드 IL15/IL15Rα 이종이량체 Fc-융합 단백질
EP3541843A1 (en) * 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
CN110198955A (zh) 2016-11-23 2019-09-03 哈普恩治疗公司 前列腺特异性膜抗原结合蛋白质
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
AU2018219909A1 (en) 2017-02-10 2019-09-12 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
KR20240011262A (ko) 2017-02-21 2024-01-25 리제너론 파아마슈티컬스, 인크. 폐암의 치료를 위한 항-pd-1 항체
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
WO2018174274A1 (ja) * 2017-03-24 2018-09-27 全薬工業株式会社 抗ＩｇＭ／Ｂ細胞表面抗原二重特異性抗体
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
EP3630829A1 (en) 2017-06-02 2020-04-08 H. Hoffnabb-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3642236A1 (en) 2017-06-20 2020-04-29 TeneoOne, Inc. Anti-bcma heavy chain-only antibodies
EP3642237A2 (en) 2017-06-20 2020-04-29 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
CA3067603A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
KR20210084695A (ko) 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
WO2019045856A1 (en) * 2017-08-28 2019-03-07 Systimmune, Inc. ANTI-CD ANTIBODIES AND METHODS OF MAKING AND USING THEM
WO2019060823A1 (en) * 2017-09-22 2019-03-28 The Regents Of The University Of California INTERFÉRON-GAMMA MITIGATES ANTITUMOR IMMUNE RESPONSE TO A BLOCKING OF CONTROL POINTS
JP2021500865A (ja) * 2017-09-29 2021-01-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． スタフィロコッカス（Ｓｔａｐｈｓｙｌｏｃｏｃｃｕｓ）標的抗原および補体成分に結合する二重特異性抗原結合分子ならびにその使用
CR20200196A (es) 2017-10-13 2020-06-05 Harpoon Therapeutics Inc Proteínas trispecìficas y mètodos de uso
SG11202003341UA (en) 2017-10-13 2020-05-28 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
CA3078911A1 (en) 2017-10-14 2019-04-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
KR101973060B1 (ko) * 2017-10-20 2019-04-26 주식회사 녹십자 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3086199A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
CN111479618B (zh) 2017-12-22 2022-08-02 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
KR20200104342A (ko) 2017-12-22 2020-09-03 테네오바이오, 인코포레이티드 Cd22에 결합하는 중쇄 항체
AU2019215363A1 (en) 2018-01-31 2020-07-23 Regeneron Pharmaceuticals, Inc. System and method for characterizing size and charge variant drug product impurities
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
EP3749361A1 (en) 2018-02-08 2020-12-16 F. Hoffmann-La Roche AG Bispecific antigen-binding molecules and methods of use
CN111787948A (zh) 2018-02-09 2020-10-16 健玛保 包含针对cd3和cd20的双特异性抗体的药物组合物及其用途
MX2020008988A (es) 2018-02-28 2020-09-28 Regeneron Pharma Sistemas y metodos para la identificacion de contaminantes virales.
JP7315565B2 (ja) 2018-03-19 2023-07-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド マイクロチップキャピラリー電気泳動アッセイおよび試薬
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
EP3781599A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
EA202092847A1 (ru) * 2018-05-24 2021-04-20 Янссен Байотек, Инк. Антитела к cd3 и их применение
CN110540593B (zh) * 2018-05-29 2022-05-17 上海药明生物技术有限公司 新型的抗cd3/抗cd20双特异性抗体
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN112351820A (zh) 2018-06-21 2021-02-09 瑞泽恩制药公司 双特异性抗psma x抗cd28抗体及其用途
WO2020018820A1 (en) 2018-07-19 2020-01-23 Regeneron Pharmaceuticals, Inc. BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
EA202190601A1 (ru) 2018-08-23 2021-07-14 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FCER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FCΕR1Α И CD3, И ИХ ПРИМЕНЕНИЕ
CA3100035A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
CN112601963B (zh) 2018-08-30 2024-05-24 瑞泽恩制药公司 用于表征蛋白质复合物的方法
MX2021002190A (es) 2018-08-31 2021-05-14 Regeneron Pharma Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20.
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2020072821A2 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
CA3116717A1 (en) 2018-10-31 2020-05-07 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying a protein
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US11249089B2 (en) 2018-12-12 2022-02-15 Regeneron Pharmaceuticals, Inc. System and method of analysis of a protein using liquid chromatography-mass spectrometry
CA3124168A1 (en) 2018-12-19 2020-06-25 Regeneron Pharmaceuticals, Inc. Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof
CA3123420A1 (en) 2018-12-19 2020-06-25 Regeneron Pharmaceuticals, Inc. Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
EP3857237B1 (en) 2019-01-16 2023-03-01 Regeneron Pharmaceuticals, Inc. Methods for characterizing disulfide bonds
US20220169728A1 (en) * 2019-01-28 2022-06-02 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
WO2020163646A1 (en) * 2019-02-08 2020-08-13 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
WO2020167919A1 (en) 2019-02-12 2020-08-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
AU2020227580A1 (en) * 2019-02-25 2021-09-30 Pharmabcine Inc. Anti-Ang2 antibody and use thereof
MX2021010390A (es) 2019-03-01 2021-11-17 Xencor Inc Anticuerpos heterodimericos que se unen a enpp3 y cd3.
CA3134335A1 (en) 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
MA55551A (fr) * 2019-04-04 2022-02-09 Janssen Biotech Inc Anticorps anti-hla-c et leurs utilisations
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
KR20220007586A (ko) 2019-05-13 2022-01-18 리제너론 파마슈티칼스 인코포레이티드 개선된 경쟁적 리간드 결합 검정
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CA3141914A1 (en) * 2019-06-07 2020-12-10 Adimab, Llc Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use
AR119746A1 (es) 2019-06-14 2022-01-05 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CN112111012B (zh) * 2019-06-20 2023-07-04 成都恩沐生物科技有限公司 共价多特异性抗体
JP2022537019A (ja) 2019-06-21 2022-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
TW202120553A (zh) * 2019-08-15 2021-06-01 美商再生元醫藥公司 用於細胞靶向之多特異性抗原結合分子及其用途
BR112022002653A2 (pt) 2019-08-15 2022-05-03 Genmab As Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit de partes
CN112390882A (zh) * 2019-08-19 2021-02-23 杨洋 靶向cd3和cd20的双特异性抗体及其应用
RU2738802C1 (ru) * 2019-08-21 2020-12-17 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
CA3216345A1 (en) 2019-09-24 2021-04-01 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
EP4065086A1 (en) 2019-11-25 2022-10-05 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
US11919965B2 (en) * 2019-12-06 2024-03-05 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
WO2021112925A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
TW202135860A (zh) 2019-12-10 2021-10-01 美商再生元醫藥公司 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
AU2020403145A1 (en) 2019-12-13 2022-07-07 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CA3165060C (en) 2020-01-21 2023-06-20 Yiming Zhao Deglycosylation methods for electrophoresis of glycosylated proteins
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
JP2023527609A (ja) 2020-02-21 2023-06-30 ハープーン セラピューティクス，インク． Ｆｌｔ３結合タンパク質および使用方法
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
BR112022021690A2 (pt) 2020-04-29 2022-12-20 Teneobio Inc Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
CA3180569A1 (en) 2020-05-01 2021-11-04 Regeneron Pharmaceuticals, Inc. Neutralizing antibody assay for therapeutic proteins
WO2021224499A1 (en) 2020-05-08 2021-11-11 Genmab A/S Bispecific antibodies against cd3 and cd20
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
JP2023538716A (ja) 2020-06-19 2023-09-11 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ３及びｃｄ１９に結合する抗体
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
CN112062855A (zh) * 2020-08-26 2020-12-11 康诺亚生物医药科技（成都）有限公司 一种含有衔接器的药物治疗剂的开发和应用
JP2023542820A (ja) 2020-08-31 2023-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 細胞培養成績を改善し、アスパラギン配列バリアントを軽減するためのアスパラギン供給戦略
AU2021339006A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
KR20230066393A (ko) 2020-09-10 2023-05-15 젠맵 에이/에스 여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
WO2022053654A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
IL301096A (en) 2020-09-10 2023-05-01 Genmab As Bispecific antibodies against CD3 and CD20 for the treatment of chronic lymphocytic leukemia
WO2022053656A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
WO2022056199A1 (en) * 2020-09-11 2022-03-17 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
IL301037A (en) 2020-09-18 2023-05-01 Regeneron Pharma Antigen binding molecules that bind CD38 and/or CD28 and uses thereof
EP4222171A1 (en) 2020-10-02 2023-08-09 Regeneron Pharmaceuticals, Inc. Combination of antibodies for treating cancer with reduced cytokine release syndrome
KR20230113280A (ko) 2020-11-25 2023-07-28 리제너론 파마슈티칼스 인코포레이티드 비수성 멤브레인 유화법을 사용한 지속 방출 제형
MX2023007225A (es) 2020-12-17 2023-06-27 Regeneron Pharma Fabricacion de microgeles encapsuladores de proteina.
JP2024503408A (ja) 2021-01-20 2024-01-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 細胞培養におけるタンパク質力価の改善方法
EP4284512A1 (en) 2021-01-28 2023-12-06 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
JP2024512299A (ja) 2021-03-03 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質の粘度を定量及び変更するためのシステム及び方法
AU2022232375A1 (en) 2021-03-09 2023-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
BR112023018665A2 (pt) 2021-03-26 2023-10-03 Regeneron Pharma Métodos e sistemas para desenvolvimento de protocolos de mistura
JP2024517535A (ja) 2021-04-30 2024-04-23 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体と抗ｃｄ７９ｂ抗体薬物コンジュゲートを用いた併用治療の投与
IL307821A (en) 2021-04-30 2023-12-01 Hoffmann La Roche Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
BR112023024984A2 (pt) 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
EP4355778A1 (en) 2021-06-17 2024-04-24 Boehringer Ingelheim International GmbH Novel tri-specific binding molecules
WO2022266660A1 (en) * 2021-06-17 2022-12-22 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
WO2023028612A2 (en) 2021-08-27 2023-03-02 Board Of Regents, The University Of Texas System Anti-tslpr (crlf2) antibodies
WO2023039457A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
WO2023051656A1 (zh) * 2021-09-30 2023-04-06 贝达药业股份有限公司 双特异性抗体及其应用
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
WO2023059803A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
CN118176167A (zh) 2021-10-26 2024-06-11 瑞泽恩制药公司 用于产生实验室用水和分配处于不同温度的实验室用水的系统和方法
US20230181644A1 (en) 2021-10-28 2023-06-15 Lyell Immunopharma, Inc. Methods of generating cells
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023138551A1 (zh) * 2022-01-20 2023-07-27 上海君实生物医药科技股份有限公司 抗cd3和抗cd20双特异性抗体及其用途
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
TW202346856A (zh) 2022-03-18 2023-12-01 美商里珍納龍藥品有限公司 分析多肽變體的方法及系統
US20230414750A1 (en) 2022-03-23 2023-12-28 Hoffmann-La Roche Inc. Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
TW202346356A (zh) * 2022-03-23 2023-12-01 大陸商上海濟煜醫藥科技有限公司 抗cd3抗體、其製備方法及應用
WO2023192850A1 (en) 2022-03-29 2023-10-05 Ngm Biopharmaceuticals, Inc. Ilt3 and cd3 binding agents and methods of use thereof
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023201226A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2023198727A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2023198839A2 (en) 2022-04-13 2023-10-19 Genmab A/S Bispecific antibodies against cd3 and cd20
WO2023214960A1 (en) 2022-05-02 2023-11-09 Regeneron Pharmaceuticals, Inc. Biochemical assays for therapeutic proteins
US20230416396A1 (en) 2022-05-18 2023-12-28 Regeneron Pharmaceuticals, Inc. Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
WO2023235805A2 (en) * 2022-06-01 2023-12-07 The Wistar Institute Of Anatomy And Biology Dna-encoded bispecific antibodies targeting carbonic anhydrase 9 and methods of use in cancer therapeutics
WO2024012513A1 (en) * 2022-07-13 2024-01-18 Hansoh Bio Llc Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
US20240043560A1 (en) 2022-08-02 2024-02-08 Regeneron Pharmaceuticals, Inc. Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 Antibodies
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
CN116023499B (zh) * 2022-10-26 2024-01-23 北京力邦生物医药科技有限公司 一种针对cd3和cd20的双特异性抗体
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024123698A1 (en) 2022-12-08 2024-06-13 Regeneron Pharmaceuticals, Inc. Methods to characterizing a fragment crystallizable domain of a bispecific antibody

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
DK0826696T3 (da) 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
BRPI9909860B8 (pt) 1998-04-21 2021-05-25 Amgen Res Munich Gmbh polipeptídeo multifuncional de cadeia simples, polinucleotídeo, vetor, célula procariótica, de levedura ou unicelular, composição, usos de polipeptídeo e polinucleotídeo e métodos para preparo do referido polipeptídeo e para identificação de ativadores ou inibidores de ativação ou estimulação das células t
EA004107B1 (ru) 1998-08-11 2003-12-25 Айдек Фармацевтикалс Корпорэйшн Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
DK1176981T3 (da) 1999-05-07 2006-04-10 Genentech Inc Behandling af autoimmune sygdomme med antagonister som binder til B celleoverflademarkörer
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ITMI991299A1 (it) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN101914158A (zh) 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
ES2559763T3 (es) 2002-09-10 2016-02-15 Affimed Gmbh Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
KR20090088973A (ko) * 2002-10-17 2009-08-20 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
CA2897608C (en) 2003-05-09 2018-07-31 Duke University Cd20-specific antibodies and methods employing same
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
JP5010281B2 (ja) * 2003-05-31 2012-08-29 マイクロメット アクツィエン ゲゼルシャフト Ｅｐｃａｍに対する二重特異性抗体を含む薬学的組成物
AU2004242845B2 (en) * 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
RU2006110036A (ru) 2003-08-29 2006-08-10 Дженентек, Инк. (Us) Лечение глазных расстройств анти-cd20
BRPI0415457A (pt) * 2003-10-16 2006-12-05 Micromet Ag constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo
US20050191297A1 (en) 2003-12-19 2005-09-01 Genentech, Inc. Detection of CD20 in transplant rejection
US7339198B2 (en) 2004-01-16 2008-03-04 Yu-Nung Shen Light-emitting diode chip package body and packaging method thereof
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
SG175659A1 (en) 2004-05-05 2011-11-28 Genentech Inc Preventing autoimmune disease by using an anti-cd20 antibody
SG10201606980VA (en) * 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
MXPA06014067A (es) 2004-06-04 2007-02-15 Genentech Inc Metodo para tratar lupus.
KR20070100228A (ko) 2004-10-05 2007-10-10 제넨테크, 인크. 혈관염의 치료 방법
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AR053579A1 (es) 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
EP1874350A2 (en) 2005-04-22 2008-01-09 Genentech, Inc. Method for treating dementia or alzheimer's disease with a cd20 antibody
JP2008541758A (ja) 2005-06-02 2008-11-27 アストラゼネカ エービー Ｃｄ２０に対する抗体およびその使用
EP2500358A3 (en) * 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
BRPI0615026A8 (pt) * 2005-08-19 2018-03-06 Abbott Lab imunoglobulina de domínio variável duplo e seus usos
AU2006301492B2 (en) * 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
EP1820513A1 (en) * 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
US7582298B2 (en) 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2155788B1 (en) 2007-04-03 2012-06-27 Micromet AG Cross-species-specific bispecific binders
AU2008234020B2 (en) * 2007-04-03 2013-02-07 Amgen Research (Munich) Gmbh Cross-species-specific CD3-epsilon binding domain
PL2155783T5 (pl) * 2007-04-03 2023-03-13 Amgen Research (Munich) Gmbh Swoista międzygatunkowo domena wiążąca CD3epsilon
PL2178916T3 (pl) * 2007-07-31 2015-08-31 Regeneron Pharma Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania
MY153781A (en) 2007-08-10 2015-03-13 Regeneron Pharma High affinity human antibodies to human nerve growth factor
AU2008295140A1 (en) * 2007-09-05 2009-03-12 F. Hoffmann-La Roche Ag Combination therapy with type I and type II anti-CD20 antibodies
WO2009106096A1 (en) * 2008-02-27 2009-09-03 Fresenius Biotech Gmbh Treatment of resistant tumors with trifunctional antibodies
EP2918604B1 (en) 2008-11-07 2017-12-20 Amgen Research (Munich) GmbH Treatment of pediatric acute lymphoblastic leukemia
RU2522002C2 (ru) * 2009-06-26 2014-07-10 Ридженерон Фармасьютикалз, Инк. Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
AU2010343057B2 (en) * 2009-12-29 2017-02-23 Aptevo Research And Development Llc Heterodimer binding proteins and uses thereof
HUE026229T2 (en) 2010-02-08 2016-06-28 Regeneron Pharma Common light chain mouse
CN102250245B (zh) * 2010-05-27 2014-05-14 四川大学 抗b细胞淋巴瘤的双特异性抗体及其用途
PT2647707T (pt) 2010-11-30 2018-11-15 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de toxicidade
ES2709065T7 (es) * 2011-02-08 2021-12-09 Medimmune Llc Anticuerpos que se unen específicamente a la toxina alfa de Staphylococcus aureus y métodos de uso
US20140154253A1 (en) 2012-07-13 2014-06-05 Zymeworks Inc. Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
SG10201800982QA (en) 2013-07-05 2018-03-28 Genmab As Humanized or chimeric cd3 antibodies
CA2917886A1 (en) 2013-07-12 2015-01-15 Zymeworks Inc. Bispecific cd3 and cd19 antigen binding constructs
PE20210107A1 (es) 2013-12-17 2021-01-19 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物

Also Published As

Publication number Publication date
KR20150046789A (ko) 2015-04-30
IL268369A (en) 2019-09-26
HUE065481T2 (hu) 2024-05-28
NZ706232A (en) 2018-11-30
EP2897981B1 (en) 2023-06-07
RS65123B1 (sr) 2024-02-29
CN104640881A (zh) 2015-05-20
TWI697502B (zh) 2020-07-01
PH12019502070A1 (en) 2021-01-18
IL268369B (en) 2021-02-28
KR102163136B1 (ko) 2020-10-12
US11072656B2 (en) 2021-07-27
IL237301A0 (en) 2015-04-30
JOP20200237A1 (ar) 2022-10-30
NZ742078A (en) 2020-01-31
US20180215823A1 (en) 2018-08-02
AU2020239677B2 (en) 2024-02-08
BR112015005380B1 (pt) 2022-11-29
CN104640881B (zh) 2021-11-05
ES2948807T3 (es) 2023-09-19
CA3135724A1 (en) 2014-03-27
JP7490857B2 (ja) 2024-05-27
HK1212996A1 (zh) 2016-06-24
PT2897981T (pt) 2023-06-27
RS64378B1 (sr) 2023-08-31
CN110041429A (zh) 2019-07-23
AU2018232926A1 (en) 2018-10-04
CL2020003179A1 (es) 2021-04-30
AU2020239677A1 (en) 2020-10-15
FI2897981T3 (fi) 2023-07-04
EA033400B1 (ru) 2019-10-31
JP2019214591A (ja) 2019-12-19
MY179577A (en) 2020-11-11
AR092612A1 (es) 2015-04-29
CO7400860A2 (es) 2015-09-30
KR20200116548A (ko) 2020-10-12
HRP20230844T1 (hr) 2023-11-10
BR112015005380A2 (pt) 2017-08-08
PL2897981T3 (pl) 2023-11-20
PH12015500328A1 (en) 2015-03-30
SG11201501269XA (en) 2015-03-30
SI3778641T1 (sl) 2024-01-31
SI2897981T1 (sl) 2023-07-31
IL237301B (en) 2020-08-31
EP2897981A1 (en) 2015-07-29
FI3778641T3 (fi) 2023-12-15
JP7330228B2 (ja) 2023-08-21
JO3716B1 (ar) 2021-01-31
TW202039579A (zh) 2020-11-01
JP6923292B2 (ja) 2021-08-18
JOP20200236A1 (ar) 2017-06-16
HRP20240149T1 (hr) 2024-04-12
CN113980132A (zh) 2022-01-28
KR102470709B1 (ko) 2022-11-28
CA2885156A1 (en) 2014-03-27
CA2885156C (en) 2021-12-07
DK2897981T3 (da) 2023-07-10
JP6865324B2 (ja) 2021-04-28
JP2021020961A (ja) 2021-02-18
ES2968913T3 (es) 2024-05-14
PH12015500328B1 (en) 2015-03-30
US9657102B2 (en) 2017-05-23
US20140088295A1 (en) 2014-03-27
CN110041429B (zh) 2023-01-03
LT3778641T (lt) 2023-12-11
JP2023100964A (ja) 2023-07-19
PL3778641T3 (pl) 2024-04-02
EP4309740A3 (en) 2024-06-05
LT2897981T (lt) 2023-07-10
AU2018232926B2 (en) 2020-06-25
TW201418282A (zh) 2014-05-16
UY35042A (es) 2014-04-30
CL2015000713A1 (es) 2015-07-10
WO2014047231A1 (en) 2014-03-27
SG10202111095XA (en) 2021-11-29
TWI618716B (zh) 2018-03-21
TW201945398A (zh) 2019-12-01
EP4309740A2 (en) 2024-01-24
EP3778641A1 (en) 2021-02-17
JP2021130701A (ja) 2021-09-09
MX2020004119A (es) 2020-08-10
US20220144947A1 (en) 2022-05-12
TWI688573B (zh) 2020-03-21
AU2013318059B2 (en) 2018-10-18
AU2013318059C1 (en) 2020-10-15
DK3778641T3 (da) 2023-12-11
JP2015535828A (ja) 2015-12-17
TW201809007A (zh) 2018-03-16
SG10201704833WA (en) 2017-07-28
MX2015003206A (es) 2015-07-14
EP3778641B1 (en) 2023-11-08
US20170320948A1 (en) 2017-11-09
CL2017001729A1 (es) 2018-03-16
HUE063215T2 (hu) 2024-01-28
AU2013318059A1 (en) 2015-04-09
US11155621B2 (en) 2021-10-26
PT3778641T (pt) 2023-12-18

Similar Documents

Publication Publication Date Title
EA201590613A1 (ru) Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения
EA201890368A1 (ru) Антитела против псма, биспецифичные антигенсвязывающие молекулы, которые связывают псма и cd3, и их применение
EA201691858A1 (ru) Композиции антител для лечения опухолей
EA201890785A1 (ru) Оптимизированные биспецифические анти-cd3 антитела и их применение
EA202191580A1 (ru) Биспецифичные антитела анти-cd28 x анти-cd22 и их применение
EA201990781A1 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
MX2018010776A (es) Moleculas de union de antigeno multiespecificas y usos de las mismas.
MX2023003418A (es) Moleculas multiespecificas de union a antigenos y usos de estas.
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
MX2021015271A (es) Uso de moleculas biespecificas de union a antigeno que se unen a psma y cd3 en combinacion con la estimulacion conjunta de 4-1bb.
EA201991227A1 (ru) Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения
EA202190089A1 (ru) Биспецифичные антитела анти-psma x анти-cd28 и их применения
EA202090303A3 (ru) Композиции антител для лечения опухолей
EA202191677A1 (ru) Биспецифичные антитела анти-muc16 x анти-cd28 и варианты их применения
EA201990779A1 (ru) Биспецифичные анти-muc16-cd3 антитела и конъюгаты анти-muc16-лекарственное средство
AR099798A1 (es) Métodos y composiciones de anticuerpos para el tratamiento de tumores